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BACKGROUND & AIMS: Little is known about the effects of endoscopic balloon dilation (EBD) for strictures of the upper
gastrointestinal (UGI) tract in patients with Crohn’s disease (CD). We performed a pooled
analysis of the efﬁcacy and safety of EBD for UGI CD-associated strictures.
METHODS: We searched Embase, Medline, and the Cochrane library, as well as bibliographies of relevant
articles, for cohort studies of adults with CD and strictures of the stomach or duodenum (up to
the ligament of Treitz) who underwent EBD through December 2016. We obtained data from
7 international referral centers on 94 patients who underwent 141 EBDs. We performed
a patient-level meta-analysis of data from published and unpublished cohort studies to
determine mechanical and clinical success. We performed a time-to-event analysis to assess
symptom recurrence and need for redilation or surgery. The patients analyzed had strictures of
the duodenum (n [ 107), stomach (n [ 30), or spanning both (n [ 4).
RESULTS: The rate of technical success for EBD was 100%, with 87% short-term clinical efﬁcacy; major
complications arose from 2.9% of all procedures. During a median follow-up period of 23.1
months, 70.5% of patients had a recurrence of symptoms, 59.6% required redilation, and
30.8% required surgical intervention. Patients whose disease was located in the small bowel
had a higher risk for symptom recurrence (hazard ratio [HR], 2.1; P [ .003). Asian race (HR,
2.8; P < .001) and location of disease in the small bowel (HR, 1.9; P[ .004) increased the need
for redilation. Prestenotic dilation was a risk factor for needing surgery earlier (HR, 1.9;
P [ .001).
Abbreviations used in this paper: CD, Crohn’s disease; EBD, endoscopic
balloon dilatation; GI, gastrointestinal; HR, hazard ratio; TNF, tumor ne-
crosis factor.
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CONCLUSIONS: In a meta-analysis, we found EBD for CD-associated strictures of the UGI to be an effective
alternative to surgery, with a high rate of short-term technical and clinical success, moderate
long-term efﬁcacy, and an acceptable rate of complications.
Keywords: Therapy; Fibrosis; Stenosis; IBD; Endoscopy.
Crohn’s disease (CD) may affect the entire gastro-intestinal (GI) tract.1 As a consequence of trans-
mural inﬂammation and a relapsing and remitting
disease course, clinically apparent ﬁbrostenosis of the
intestine occurs in 20% of patients within 20 years after
initial diagnosis.2 Despite recent advances in the medical
treatment of CD, prevention and treatment of stricturing
CD remains a large, unmet need.3 Because of the absence
of speciﬁc antiﬁbrotic therapies,4 CD patients with in-
testinal obstruction are commonly treated by surgical
intervention such as strictureplasty or bowel resection,5
both of which can be associated with signiﬁcant
complications.6,7
Although CD may affect all parts of the GI tract,
involvement of the stomach and duodenum is
rarely reported. More speciﬁcally, the incidence of
CD-associated strictures of the upper GI tract is less than
4%.8 Beside the occurrence of strictures, ﬁstulae devel-
opment in the upper GI tract has been reported as
well.9,10 Historically, in the presteroid era, surgery
was the only available treatment modality for obstructive
duodenal CD, but often was accompanied by a
complicated postoperative course with postoperative
abscesses.11,12 Since then, with the advent of corticoste-
roids and immunosuppressive drugs, some case reports
have become available that illustrate cases with an at
least temporary successful medical treatment.8,9,11
Therefore, stricturing as well as ﬁstulizing complica-
tions of the upper GI tract may generate challenging
clinical scenarios for both affected CD patients as well as
health care providers alike. The very limited body of
published evidence for this treatment scenario is aggra-
vates this clinical dilemma further.
Endoscopic balloon dilation (EBD) has emerged as
an alternative to surgery and has been proven effec-
tive for the treatment of ﬁbrotic CD-associated
strictures of the ileocecum. EBD therefore has been
implemented in current CD treatment algorithms and
guidelines.13–15 EBD for CD-associated strictures of the
upper GI tract was reported rarely in a large cohort
comprising 35 patients from a single center.16 There-
fore, the aim of this pooled analysis of international
multicenter cohort studies, combining published
cohorts with a multicenter investigation for a patient-
level meta-analysis, was to evaluate the safety and
efﬁcacy of EBD in upper GI CD-associated strictures
and to provide evidence-based guidance for this clin-
ical situation.
Materials and Methods
Literature Search and Data
Detailed information regarding the literature search
and data, as well as a PRISMA diagram (Supplementary
Figure 1) can be found in the Supplementary materials.
Corresponding authors of articles that fulﬁlled the in-
clusion and exclusion criteria were contacted via e-mail
to obtain single patient-level data for the subjects
included in the studies. These data represent part 1 of
the pooled individual patient analysis.
In addition, 7 high-volume inﬂammatory bowel dis-
ease endoscopy centers were contacted and they pro-
vided clinical data for a total of 24 patients. These data
represent part 2 of the pooled individual patient analysis.
Of note, comparable criteria were used to assess the
performance of dilation procedures as well as treatment
outcomes in relation to the already published studies
and as deﬁned later.
Data Collection
The deﬁnitions used for the explored parameters of
included studies16–19 are reported in the Supplementary
Materials and Methods section and Supplementary
Table 1.
Statistical Analysis
Detailed information about the statistical analysis can
be found in the Supplementary Materials and Methods
section.
Results
Pooled Individual Patient Analysis
In total, we included 94 patients from 11 different
tertiary referral centers for inﬂammatory bowel disease
(located in the United States, Australia, China, Japan,
Denmark, Germany, The Netherlands, and Switzerland).
There were 141 total dilation procedures. Seventy
patients undergoing 112 dilations have been published
in multiple individual smaller series previously,16–21 and
24 patients undergoing 29 dilations were not in previ-
ously published reports but were added through our
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multicenter collaboration (Table 1). The demographics of
this population are shown in Table 2. The median age at
CD diagnosis was 24  10.6 years, and the median age at
the time of stricture diagnosis was 33.7  14.3 years. A
total of 75.9% of strictures were located in the duo-
denum, 21.3% of patients developed strictures in the
stomach, and 2.8% of patients presented with strictures
that spanned from the stomach to the duodenum
(Table 2). Most strictures were de novo strictures
(89.1%; as opposed to anastomotic strictures) at sites
without prior surgery. The median length of stricture
was 3 cm (25th percentile, 2; 75th percentile, 10), with
85.4% of strictures being less than 5 cm long. All stric-
tures were dilated by through-the-scope systems and
70.1% of the investigators applied graded dilation. The
median maximum balloon diameter used was 15 mm
(25th percentile, 14.0 mm; 75th percentile, 18.0 mm),
and the vast majority of investigators used a balloon that
was 5.5 cm in length (25th percentile, 5.5 cm; 75th
percentile, 5.5 cm). The median time of balloon inﬂation
was 2 minutes (25th percentile, 2 min; 75th percentile, 3
min,) and a pressure of 20 psi was applied (Table 3). The
technical success rate was 100%, and EBD lead to short-
term clinical efﬁcacy in 87% of all patients. Of note,
technical success did not result in clinical improvement
of obstructive symptoms in all patients.
Major complications (deﬁned as perforation, bleeding,
or a dilation-related need for surgery) occurred in 2.9%
per procedure and in 4% per patient, considering the
possibility of multiple dilations over time in the same
study subject. During a median follow-up period of 23.1
months, 70.5% of patients reported symptomatic recur-
rence, 59.6% required another dilation, and 30.8% of all
patients had to undergo surgical intervention (Tables 2
and 3, and Figure 1A–C).
Table 1 presents descriptive statistics for patients
from each center as well as the random-effects analysis
and measures of variability. The overall rates for symp-
tom, dilation, and surgery-free survival at 6, 12, and 24
months are shown in Table 4.
To assess potential bias, we included both published
and unpublished studies (Supplementary Tables 2–5)
and performed a sensitivity analysis separately
after excluding unpublished studies (Supplementary
Tables 6–9). These results are presented and discussed
in the Supplementary Materials and Methods section of
this article and the data discussed later refer to the
complete cohort only.
Factors Associated With Short-Term Dilation
Outcome
Given the achievement of technical success in all
included subjects, no analysis for factors associated
with technical success could be performed. We hence
evaluated factors associated with the short-term clinical
efﬁcacy of dilation procedures. Patients with active
disease in the ileocecum had a lower likelihood of
symptom relief in the adjusted and unadjusted analyses
(odds ratio, 0.27; 95% CI, 0.058–1.2; P ¼ .087 and odds
ratio, 0.27; 95% CI, 0.06–1.2; P ¼ .083, respectively).
No other factor was linked to clinical efﬁcacy
(Supplementary Table 2).
Factors Associated With Symptom Recurrence
We next assessed factors associated with symptom
recurrence. In univariate analysis, disease location in the
jejunum/proximal ileum (hazard ratio [HR], 1.8; 95% CI,
1.09–2.9; P ¼ .022) was associated with an increased
hazard for symptom recurrence. In contrast, a stricture
length shorter than 5 cm (HR, 0.41; 95% CI, 0.24–0.7;
P ¼ .001) was associated negatively with time to
symptom recurrence. Although disease location in the
jejunum/ileum was linked to symptom recurrence in the
multivariate analysis (HR, 2.1; 95% CI, 1.3–3.5; P ¼
.003), age at diagnosis was associated with diminished
risk (HR, 0.85; 95% CI, 0.72–1.0; P ¼ .054). Univariate
and multivariate analyses did not detect any other fac-
tors that were linked to an increased risk of symptom
recurrence (Supplementary Table 3).
What You Need to Know
Background
Intestinal strictures are a common complication of
Crohn’s disease (CD). Strictures in patients that
coincide with locations of inﬂammation and can
affect the upper gastrointestinal (UGI) tract. Little is
known about the efﬁcacy and safety of endoscopic
balloon dilation (EBD) for these patients.
Findings
We performed a meta-analysis of multicenter cohort
studies of the effects of EBD for CD-associated stric-
tures of the UGI tract. Technical and short-term
clinical success rates were 100% and 87%, respec-
tively, although major complications arose from 2.9%
of procedures. During a median follow-up period of
23.1 months, 70.5% of patients had a recurrence of
symptoms, 59.6% underwent redilation, and 30.8%
of patients required surgery. Patients with disease
locations in the small bowel had a higher hazard for
symptom recurrence and need for redilation. Pre-
stenotic dilation was a risk factor for needing surgery
earlier.
Implications for patient care
In a meta-analysis, we found EBD for CD-associated
strictures of the UGI tract to be a valuable alterna-
tive to surgery, with a high rate of short-term tech-
nical and clinical success, moderate long-term
efﬁcacy, and an acceptable rate of complications.
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Table 1. Pooled Per-Study Analysis
Study Rieder16,a Zhu19,a Matsui18,a Bettenworthb Herfarthb Hampeb Gotzb Dingb Karstensen17,a Duijvesteinb Roglerb All studies
Published
studies
Unpublished
studies
Patients, 34 23 10 4 7 4 4 1 3 2 2 94 70 24
Dilations, n (included in
study)
76 23 10 7 7 4 4 3 3 2 2 141 112 29
Stricture location
(nonexclusive)
Stomach strictures,% 26.3 13 50 0 28.6 50 0 0 0 50 50 24.1 (16.2–32.0) 25.0 (12.1–37.9) 20.7 (0.00–42.1)
Duodenum
strictures %
73.7 87 90 100 71.4 50 100 100 100 50 50 78.7 (70.4–87.1) 78.6 (64.2–93.0) 79.3 (57.9–100.0)
Strictures 5 cm, % 93.8 66.7 0 100 100 100 100 100 100 100 100 85.4 (62.3–100.0) 81.3 (28.8–100.0) 100
TTS balloon dilation, % 100 100 100 100 100 100 100 100 100 100 100 100 100 100
Maximal caliber of
dilation, mm
15 15.7 16.8 15.6 16.1 13.5 14.5 12 13.3 18 20 15.3 (14.7–15.8) 15.3 (14.3–16.2) 15.2 (13.7–16.7)
Steroid injection, % 3.9 0 0 0 28.6 0 0 0 0 0 0 3.6 (0.20–6.9) 2.7 (0.00–6.5) 7.1 (0.00–22.8)
Technical success, % 100 100 100 100 100 100 100 100 100 100 100 100 100 100
Short-term clinical
efﬁcacy, %
86.1 63.6 100 100 100 100 50 100 100 100 100 87.0 (80.1–93.9) 85.4 (74.4–96.5) 92.6 (74.1–100.0)
Major complications
per patient, %
7.1 4.3 0 0 0 0 0 0 0 0 0 4.0 (0.59–7.3) 5.1 (0.34–9.9) 0
Major complications
per procedure, %
4.2 4.3 0 0 0 0 0 0 0 0 0 2.9 (1.1–4.7) 3.7 (1.9–5.5) 0
Cutting techniques
used, %
0 0 10 0 0 0 0 0 0 0 0 0.71 (0.00–2.5) 0.89 (0.00–4.7) 0
Stent used, % 0 0 0 0 0 0 0 0 33.3 0 0 0.71 (0.00–2.6) 0.89 (0.00–4.9) 0
Redilation during
follow-up period, %
50.7 78.3 100 42.9 71.4 25 25 100 100 50 0 59.6 (43.7–75.4) 62.6 (28.3–96.9) 48.3 (22.7–73.8)
Symptomatic
recurrence during
follow-up period, %
71.2 57.1 100 83.3 71.4 0 0 50 100 50 100 70.5 (60.1–80.9) 75.0 (57.0–93.0) 56.5 (23.9–89.1)
Surgery during follow-
up period, %
32.3 34.8 30 25 28.6 25 50 100 0 0 0 30.8 (25.7–35.8) 31.3 (24.4–38.3) 29.2 (13.9–44.5)
NOTE. Overall estimates were obtained using survey methodology with study as a clustering effect. Overall estimates are shown as the pooled estimate (95% CI).
TTS, through-the-scope.
aPublished study.
bUnpublished study.
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Factors Associated With Need for Redilation
Regarding the need for redilation, univariate as well
as multivariate analyses showed that Asian race (HR,
2.8; 95% CI, 1.7–4.5; P < .001 and HR, 2.8; 95% CI,
1.8–4.5; P < .001) and disease location in the jejunum/
proximal ileum (HR, 1.7; 95% CI, 1.1–2.6; P ¼ .015 and
HR, 1.9; 95% CI, 1.2–2.9; P ¼ .004) were associated
with a signiﬁcantly increased risk of redilation
(Supplementary Table 4). None of the other investi-
gated factors, including smoking, stricture location, type
of stricture (de novo vs anastomotic), prestenotic
dilation, graded dilation or maximum caliber of dilation,
or anti–tumor necrosis factor (TNF) treatment were
linked to the need for additional endoscopic
therapy in the univariate or multivariate analyses
(Supplementary Table 4).
Factors Associated With the Need for Surgery
Prestenotic dilation was linked to an increased risk
for surgery in the univariate as well as multivariate an-
alyses (HR, 2.0; 95% CI, 1.4–2.7; P < .001 and HR, 1.9;
95% CI, 1.3–2.7; P ¼ .001, respectively) (Supplementary
Table 5). In addition, in the univariate analysis, Asian
race and younger age at time of dilation were found to be
associated with an increased risk for surgery (HR, 1.7;
95% CI, 1.2–2.3; P ¼ .003 and HR, 0.92; 95% CI,
0.87–0.98; P ¼ .007, respectively), while increased body
mass index and a positive family history of CD were
associated with a reduced risk of need for surgery, but
could not be conﬁrmed by the multivariate analysis (HR,
Table 2. Patient Characteristics
Factor
Total (N ¼ 94)
n Statistics
Female sex 94 56 (59.6)
Race/ethnicity 92
Caucasian 56 (60.9)
African American 2 (2.2)
Asian 33 (35.9)
Other 1 (1.1)
BMI 75 21.0 [17.3, 24.3]
Family history of CD 82 4 (4.9)
Smoking 84
Never 63 (75.0)
Current 11 (13.1)
Former 10 (11.9)
Age at diagnosis, y 92 24.0  10.6
Age at time of stricture diagnosis, y 94 33.7  14.3
Age at time of ﬁrst dilation, y 89 34.3  14.6
Disease location
Upper GI 93 93 (100.0)
Jejunum/proximal ileum 93 26 (28.0)
Ileocecal 92 54 (58.7)
Colon 93 41 (44.1)
Rectum 93 27 (29.0)
Any EIM 86 26 (30.2)
Upper GI strictures, n 94
1 74 (78.7)
2 18 (19.1)
3 2 (2.1)
Patient outcomes
Total follow-up time, mo 88 23.1 [9.8, 47.5]
Dilations during follow-up evaluation 73
1 25 (34.2)
2 13 (17.8)
3 14 (19.2)
4 9 (12.3)
5 12 (16.4)
Stricture surgery 91 28 (30.8)
Months to surgery 28 3.6 [1.7, 7.3]
NOTE. Statistics are presented as means  SD, median is shown as [P25, P75]
or N (column %).
BMI, body mass index; EIM, extraintestinal manifestation.
Table 3. Stricture and Dilation Characteristics
Factor
Total (N ¼ 141)
n Statistics
Stricture
Stricture location 141
Stomach 30 (21.3)
Stomach and duodenum 4 (2.8)
Duodenum 107 (75.9)
Type of stricture 64
Postsurgical/anastomotic 7 (10.9)
De novo 57 (89.1)
Length of stricture, cm 39 3.0 [2.0, 10.0]
Length of stricture 103
>5 cm 15 (14.6)
5 cm 88 (85.4)
Prestenotic dilation 136 63 (46.3)
PPI at the time of dilation 137 97 (70.8)
Anti-TNF at time of dilation 138 30 (21.7)
No therapy 138 8 (5.8)
Dilation
Graded dilation 137 96 (70.1)
Abnormal mucosa at time of dilation 139 96 (69.1)
Maximum caliber of dilation, mm 134 15.0 [14.0, 18.0]
Length of balloon, cm 46 5.5 [5.5, 5.5]
Time of balloon inﬂation 23 2.0 [2.0, 3.0]
Pressure of dilation, psi 14 20.0 [20.0, 87.0]
Steroid injection 140 5 (3.6)
Cutting techniques used 140 1 (0.71)
Stent placement 140 1 (0.71)
Outcomes of dilation
Technical success 140 140 (100.0)
Passage of scope after dilation 132 122 (92.4)
Relief of symptoms after dilation,
clinical efﬁcacy
123 107 (87.0)
Major complications per procedure 136 4 (2.9)
Redilation 136 81 (59.6)
Months to redilation 81 2.0 [1.2, 7.5]
If clinical efﬁcacy, symptom recurrence 95 67 (70.5)
Months to symptom recurrence 67 2.0 [1.00, 5.1]
Medications between ﬁrst and
second dilation
141 31 (22.0)
Duration of medical therapy between ﬁrst
and second dilation, wk
24 6.5 [4.5, 20.2]
NOTE. Statistics are presented as median [percentile25, percentile75]
or N (column %).
PPI, proton pump inhibitor.
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0.91; 95% CI, 0.87–0.96; P < .001 and HR, 0.71; 95% CI,
0.51–0.99; P ¼ .046, respectively). None of the other
investigated factors, including smoking, disease location,
type of stricture, graded dilation, or maximum caliber of
dilation, was linked to need for earlier surgery
(Supplementary Table 5).
Complications After Endoscopic Balloon
Dilation
Complications associated with dilations occurred in 5
patients. This included 2 perforations and 3 bleeding
events. No patient had to undergo dilation-associated
surgery. Because of the low number of complications in
the cohort, no meaningful analysis for risk factors could
be performed. The 2 patients who experienced a perfo-
ration were treated by their ﬁrst dilation procedure, the
stricture length was less than 5 cm, and neither patient
receive steroid treatment at the time of intervention.
Efﬁcacy of Serial Dilations of Upper
Gastrointestinal Strictures
Finally, we analyzed the efﬁcacy of repeat dilations of
the same stricture. Data on a second dilation were
available for 22 episodes, and a third dilation for 9 epi-
sodes. With regard to technical success, all second and
third dilations were successful. Although symptomatic
relief of symptoms could be achieved in 86.2% of pa-
tients through the ﬁrst dilation, clinical success was
achieved in 85% of patients treated by a second dilation
and by 88.9% of patients requiring a third dilation. The
need for redilation was documented in 61.6% of patients
after the ﬁrst dilation and in 54.5% and 66.7% of pa-
tients being treated by a second and third dilation,
respectively (all P > .05). Interestingly, time to redilation
did not differ signiﬁcantly between the ﬁrst, second, and
third dilation procedures (P > .05) (Supplementary
Table 10).
Discussion
EBD is used frequently for the treatment of CD-
associated strictures throughout the gastrointestinal
tract. A pooled analysis of 3213 dilation procedures
supports the efﬁcacy and safety of this approach.14 Most
studies, however, do not provide a separate analysis on
the use of EBD for CD-associated strictures of the upper
GI tract. More speciﬁcally, the 2 largest available studies
on this indication include only 24 and 35 patients,
respectively,16,19 precluding a thorough analysis of short-
and long-term efﬁcacy, safety, and predictors of success.
Our pooled analysis of international multicenter
cohort studies comprised individual data sets of 94 CD
patients who underwent EBD for upper GI strictures.
Although 70 of the 94 analyzed cases were published
previously, we were able to include 24 additional cases
in the analysis. We found rates for technical and clinical
success of 100% and 87%, respectively, and major
complications occurred in 2.9% per procedure. During a
median follow-up period of 23.1 months, the pooled in-
dividual patient analysis showed that 70.5% of patients
experienced symptomatic recurrence, 59.6% underwent
redilation, and 30.8% of patients required surgery. Pa-
tients with small-bowel disease location had a higher
hazard for symptom recurrence and need for redilation.
Prestenotic dilation was found to be a risk factor for
needing an earlier surgery.
A large pooled analysis of EBD for ileocecal strictures
reported technical and clinical success rates of 89.1%
and 80.8%, respectively.14 Our study shows that dilation
therapy for CD-associated strictures of the upper GI tract
Figure 1. Risk for symptomatic recurrence, redilation, and stricture surgery in patients with endoscopic balloon dilation for
primary CD-associated strictures in the upper GI tract over time. (A) Evaluating the future course after endoscopic dilation
therapy indicates that symptom recurrence occurred in 58.2% and 70.5% of patients within 6 and 12 months, respectively. (B)
Assessing the risk for redilation showed that 46.7% and 58.3% of patients required another dilation within 6 and 12 months
after initial EBD, respectively, whereas (C) 23.6% and 32.5% needed surgery within 6 and 12 months after dilation,
respectively.
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is comparably successful in the short term. The very high
technical success rate observed in our study may result
from the fact that we deﬁned this parameter differently
from prior studies by the ability to dilate the stricture
after starting the procedure (but not by the ability to
traverse the stricture after dilation). During a follow-up
period of 23 months, long-term outcome parameters
for dilation of CD-associated strictures of the upper GI
tract such as symptoms recurrence, need for redilation,
and surgery were not signiﬁcantly different compared
with the pooled data for CD-associated strictures of the
ileocecum during a follow-up period of 24 months
(70.5% vs 75.9%, 59.6% vs 73.5%, and 30.8% vs 42.9%,
respectively),14 which came as a surprise given the
common belief of clinicians that upper GI CD-associated
stricture dilation is less durable. Finally, the complica-
tions rates per dilation procedure for ileocecal and upper
GI strictures were comparable (2.8% vs 2.9%).14 These
results are also in line with ﬁndings from other meta-
analyses on EBD for CD-associated strictures.22,23 We
were not able to assess if ﬂuoroscopy impacted the
complication rates of EBD because the vast majority of
investigators reported using ﬂuoroscopy at the discre-
tion of the endoscopist and did not record its perfor-
mance systematically. Taken together, our study
provides evidence that endoscopic dilation of CD-
associated strictures of the upper GI tract by EBD is
effective and safe, with rates comparable with dilation
therapy for CD-associated strictures of the ileocecum.
Identiﬁcation of predictive factors for the long-term
success of EBD of the upper GI tract would allow risk
stratiﬁcation of patients beneﬁtting from a procedure.
Patients with disease location in the jejunum/proximal
ileum showed a higher rate of symptom recurrence and
need for redilation. The patients with prestenotic dilation
were at a higher risk for surgery. Prestenotic dilation is a
feature that is not observed in every patient with stric-
turing CD but is regarded as a sign of advanced, longer-
standing strictures with a higher ﬁbrotic component,
even though evidence supporting this notion is limited.
In our cohort, patients’ symptoms were less likely to
improve when prestenotic dilation was present and the
time to surgery was shorter. This is in concordance with
the recently published efﬁcacy of adalimumab in patients
with Crohn's disease and symptomatic small bowel
stricture study, which evaluated the efﬁcacy of anti-TNF
treatment for symptomatic small-bowel strictures.3 Pa-
tients with prestenotic dilation were at an increased risk
for surgery. Because jejunal/proximal ileal disease was
found to be associated negatively with symptom recur-
rence and need for redilation, it can be hypothesized that
CD patients with disease manifestation at different lo-
cations along the GI tract may suffer from a more severe
phenotype, or symptoms classiﬁed as obstructive origi-
nating from other regions of the GI tract. This assump-
tion is supported by data from population-based studies
indicating that CD patients with ileal involvement at the
time of diagnosis are at an increased risk for a more
aggressive disease phenotype.2 Interestingly, race
showed an effect on dilation efﬁcacy. Aside from the fact
that Asians may have a higher risk for stricture recur-
rence, it may be explained by different strategies for the
utilization of endoscopy and management strategies in
this region.
Interestingly, active smoking was not found to be a
risk factor for worse outcome of dilation therapy in our
study. There is a body of evidence indicating the smoking
aggravates the course of CD,24,25 increases the risk of
postoperative recurrence,26,27 and smoking cessation
decreases the risk for CD-related surgery.28 One study29
reported an increased risk for stricture recurrence after
endoscopic dilation, however, the included patients suf-
fered exclusively from ileocecal strictures.
Given the fact that stricture development follows the
location of inﬂammation, it is logical that an early
appropriate medical treatment of inﬂammatory CD of the
upper GI tract may be the best approach to prevent the
occurrence of CD-associated strictures. Indeed, a study
by Decker et al30 evaluating 20 patients with esophageal
CD from the Mayo Clinic (Rochester, MN) in the pre–anti-
TNF era found modest treatment effects of steroids or
immunomodulatory therapy (clinical response rates,
67% and 55%, respectively), and 3 of 20 patients ﬁnally
required esophagectomy. In contrast, the ﬁndings from a
more recent study from the same institution analyzing
24 cases of esophageal CD showed that early aggressive
therapy including different anti-TNF agents and systemic
and topical steroid therapy resulted in the complete
resolution of clinical symptoms in 83% of patients and
prevented surgical interventions in all patients.31 Future
prospective studies will need to show whether early
biologic therapy can prevent the occurrence of strictures
or their need for redilation or surgery.
Our study had several limitations. Individual patient
data sets were retrieved from 11 different centers and
variations in the care patterns and approaches of the
endoscopists may have inﬂuenced the results. In addi-
tion, and as delineated in the Materials and Methods
section, deﬁnitions regarding parameters such as tech-
nical success and clinical efﬁcacy differed between
various studies. Key features, however, such as the use of
through-the-scope balloons in all cases, maximum caliber
of dilations, as well as the duration and pressure of
Table 4. Postdilation Event Rates
Postdilation
follow-up period, mo Surgery Redilation
Symptom
recurrence
6 23.6
(13.4–32.6)
46.7
(37.2–54.7)
58.2
(44.4–68.6)
12 32.5
(20.5–42.8)
58.3
(48.0–66.5)
70.5
(57.9–79.3)
24 44.3
(28.7–56.5)
67.1
(56.5–75.2)
78.3
(64.9–86.6)
NOTE. Values are presented as the cumulative rate (95% CI).
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balloon inﬂation, were quite similar among different
centers. Furthermore, we were not able to exclude
publication or reporting bias so that patients in whom
dilation therapy could not be technically performed may
have been under-represented in available publications.
The retrospective noncontrolled observational nature of
the study did not allow randomization based on risk
factors or other criteria. Finally, the time point of eval-
uation of clinical efﬁcacy was not standardized across
studies. However, clinical efﬁcacy was measured closely
to dilation in all cases because symptom relief occurs
almost immediately postprocedure. According to the
Cochrane risk of bias tool, our study carries all potential
inherent biases of cohort studies with retrospective data
collection. In addition, reporting bias may apply because
our study was a pooled analysis of already published
studies. Centers with poor outcomes or high complica-
tion rates may not publish their cases. However, the
largest published study included in this investigation by
Singh et al16 included all dilations performed at this
tertiary center. Finally, because we have incomplete data
for some variables and outcomes attrition, bias may
apply. However, of the 39 items assessed for patient
characteristics, stricture characteristics, and outcome, 29
items were available in 85% of included patients or
more. In particular, short- and long-term outcome pa-
rameters were available for the vast majority of patients.
Although our study adds important information to the
literature, from a clinical point of view, our study cannot
fully answer the question about which patients are
treated best by EBD and which by surgical intervention.
This clinical dilemma would require a head-to-head trial
of the 2 modalities. The main value of this investigation
lies in providing practicing providers with robust data for
informed decision making in patients with upper GI CD.
Taken together, the results of this large multicenter
evaluation of EBD for CD-associated strictures of the
upper GI tract show high rates of short-term technical
and clinical success. Given the moderate long-term efﬁ-
cacy and acceptable complication rate, EBD is a valuable
treatment option in patients with stricturing CD of the
upper GI tract when contraindications such as abscess,
ﬁstula, phlegmon, dysplasia, or malignancy have been
excluded.
Supplementary Material
Note: To access the supplementary material accom-
panying this article, visit the online version of Clinical
Gastroenterology and Hepatology at www.cghjournal.org,
and at https://doi.org/10.1016/j.cgh.2018.11.048.
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Supplementary Materials and Methods
Statistical Analysis
Individual patient data meta-analysis was performed
using a 1-step approach in which data from all studies
were modeled simultaneously. Summary data were
obtained using survey methodology, with study as a
clustering effect. In addition, regression accounts for
correlations between subjects within the same study as
well as multiple dilations for the same patients.
Complete-case analysis was performed.
Short-term clinical efﬁcacy. Dilation-level data were
used to assess factors associated with clinical efﬁcacy
using generalized linear mixed models with a logit link
for binary data; random effects for center, study, and
subject were used to account for correlation between
multiple dilations performed on the same patient and
between patients seen at the same center. Only an un-
adjusted analysis was performed because fewer than 20
dilations did not achieve clinical efﬁcacy.
Redilation and recurrence of symptoms. Dilation-level
data were used to assess factors associated with recur-
rence of symptoms and need for redilation. Some di-
lations did not have follow-up information on either
redilation or symptom recurrence and were excluded
from this part of the analysis. To assess redilation,
follow-up time was deﬁned as months from current
dilation to time of redilation; subjects were censored at
the time of last follow-up visit if they had no redilations.
Symptom recurrence was assessed only in subjects with
clinical efﬁcacy, and follow-up time was deﬁned as
months from the current dilation to time of symptom
recurrence; subjects were censored at the time of redi-
lation, surgery, or last follow-up visit if they had no
recurrence. Cox marginal model regression analysis was
performed and standard errors and P values are based
on a robust (sandwich) variance estimator that accounts
for patients having multiple dilations and study clustered
data. Factors that were seen in 5 or more patients and
those that were reported for most dilations were
considered for inclusion in the multivariable model and a
stepwise variable selection method was used to choose
the ﬁnal model.
Surgery. Patient-level data were used to assess fac-
tors associated with need for surgery. There were 4
patients who had no information regarding surgery and
were excluded from this part of the analysis. Follow-up
time was deﬁned as months from the ﬁrst dilation to
time of surgery; patients were censored at the time of
last follow-up visit if they did not have surgery. Unad-
justed and multivariable Cox marginal model regression
analysis was performed to assess factors associated with
surgery; standard errors and P values were based on a
robust (sandwich) variance estimator that accounted for
patient clustering by study. Factors that were seen in 5
or more patients and those that were reported for most
dilations were considered for inclusion in the multivar-
iable model and a stepwise variable selection method
was used to choose the ﬁnal model. A P value less than
.05 was considered statistically signiﬁcant. All analyses
were performed using SAS (version 9.4; The SAS Insti-
tute, Cary, NC) or R (meta-package, version 3.3.2; The R
Institute for Statistical Computing, Vienna, Austria).
Literature Search and Data
We performed a formal systematic review with a
comprehensive literature search to identify all relevant
citations in Embase, Medline (service of the US National
Library of Medicine and the National Institutes of
Health), and the Cochrane library for the following key
words: (‘Crohn’s disease (CD)‘ OR ‘Crohn’s’ AND (‘stric-
ture’ OR ‘endoscopic dilatation’ OR ’endoscopic dilation’
OR ’balloon dilation’ OR ’balloon dilatation’)). A recursive
search of bibliographies of relevant articles also was
performed. The search included cohort studies since
inception until December 2016 and only included full-
text articles in English language. Eligible studies
enrolled adult patients (age, >18 y) with a conﬁrmed
diagnosis of CD, strictures of the stomach or duodenum
(up to the ligament of Treitz) associated with CD that
were dilated using through-the-scope endoscopic balloon
dilation. Exclusion criteria were an unclear diagnosis or
use of dilation methods other than through-the-scope
balloons. We decided to exclude patients with esopha-
geal CD because the exact etiology of esophageal stric-
tures in these patients often cannot be elucidated. This is
particularly true for the distinction between reﬂux-
related strictures and CD-associated strictures.
Two reviewers (D.B., M.M.M.) independently screened
citations and abstracts. The full-text publications of
potentially eligible studies were reviewed in duplicate by
2 pairs of researchers (D.B., M.M.M.). Disagreements
regarding inclusion or extraction were resolved through
discussion, or arbitration was performed by another
author (F.R.).
In addition, 7 high-volume inﬂammatory bowel dis-
ease endoscopy centers were contacted and asked to
contribute adult patients (age, >18 y) with a conﬁrmed
diagnosis of CD, strictures of the stomach or duodenum
(up to the ligament of Treitz) associated with CD that
were dilated using through-the-scope endoscopic balloon
dilation. Clinical data from 24 cumulative patients were
transferred into an anonymized secured database. Data
checks were performed. If discrepancies were detected
they were resolved with the respective investigators.
Ethical approval for this data collection was obtained by
each local center and data were provided in a de-
identiﬁed fashion. Nonresponding corresponding
investigators were re-contacted up to 2 times. Four of 8
contacted investigators provided their complete
data sets of 70 cumulative CD patients, whereas 4
investigators did not respond to our query. Ethical
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approval of this pooled analysis was not needed because
only published data were provided in a de-identiﬁed
fashion. Missing individual-level data were handled as
described in the Statistical Analysis section.
Data Collection
Technical success was deﬁned mainly as the ability
to dilate the stricture after starting the procedure. The
deﬁnitions for technical success as mentioned in the
individual publications can be found in Supplementary
Table 1. The deﬁnition for short-term clinical efﬁcacy
were improvement or relief of symptoms of obstruc-
tion. The deﬁnitions for clinical efﬁcacy as mentioned
in the individual publications can be found in
Supplementary Table 1. Long-term success was deﬁned
as the absence of recurrent symptoms, redilation-free
interval, and intervention-free period with no need for
surgery after the ﬁrst dilation. Major complications
were deﬁned as perforation, bleeding, or dilation-
related surgery. The need for surgery was deﬁned as
surgery at the site of the dilated stricture only. This did
not include patients who had surgery in other areas of
their intestine. For the additionally collected unpub-
lished patients the following deﬁnitions were used.
Technical success was deﬁned as the ability to dilate
the stricture after starting the procedure. The deﬁnition
for short-term clinical efﬁcacy included improvement or
relief of symptoms of obstruction. Long-term success
was deﬁned as the absence of recurrent symptoms,
redilation-free interval, and intervention-free period
with no need for surgery after the ﬁrst dilation. Major
complications were deﬁned as perforation, bleeding, or
dilation-related surgery. The need for surgery was
deﬁned as surgery at the site of the dilated stricture
only. Only symptomatic strictures with no concomitant
ﬁstula, abscess, dysplasia, or malignancy were included
in the analysis.
For the individual per-patient analysis, a protocol was
developed and items regarding demographics, disease
phenotype, medications, and dilation procedures were
collected for all included subjects. A detailed list
depicting all assessed variables is shown in Tables 2 and
3. Because we did not have access to the individual pa-
tient charts we used the descriptors provided by the
investigators and no patient was reclassiﬁed.
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GI tract
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of contacted authors 
(n=4)
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Supplementary Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses ﬂow diagram.
November 2019 Upper GI Crohn’s Disease Strictures 2522.e3
Supplementary Table 1. Deﬁnitions for Technical Success and Short-Term Clinical Efﬁcacy in the Individual Studies
Deﬁnition for technical success References
Ability to pass the scope beyond stricture after dilation 12
Passage of the endoscope through the stricture without resistance immediately after the dilation was performed safely 15
No deﬁnition provided 14
Dilatation of initially nontraversable strictures to a balloon diameter of 15 mm had been reached 13
Deﬁnition for short term clinical efﬁcacy
Relief of obstructive symptoms 12
Return to normal diet 15
Symptomatic relief (without postprandial fullness) 14
Remission of obstructive symptoms 13
Supplementary Table 2. Analysis of Factors Associated With Short-Term Clinical Efﬁcacy: Generalized Linear Mixed Models:
All Studies
Factor
Unadjusted analysis Adjusted analysis
OR (95% CI) P value OR (95% CI) P value
Female vs male 1.8 (0.46–7.3) .38 — —
Asian vs Caucasian 0.52 (0.03–8.8) .64 — —
BMI, 1-kg/m2 increment 1.2 (0.94–1.4) .16 — —
Family history of CD 0.56 (0.03–9.6) .68 — —
Smoking, past or present 5.2 (0.48–56.5) .17 — —
Age at diagnosis, 5-year increment 0.86 (0.64–1.2) .33 — —
Age at time of stricture diagnosis, 5-year increment 1.03 (0.80–1.3) .82 — —
Age at time of dilation, 5-year increment 1.1 (0.84–1.5) .40 — —
Disease in jejunum/proximal ileum 1.08 (0.23–5.0) .92 — —
Disease in ileocecum 0.27 (0.06–1.2) .083 0.27 (0.058–1.2) .087
Disease in colon 2.1 (0.48–9.5) .31 — —
Disease in rectum 4.5 (0.81–24.6) .083 — —
EIM 0.70 (0.12–4.2) .69 — —
Stomach stricture 1.08 (0.24–4.9) .92 — —
Duodenum stricture 1.05 (0.23–4.9) .95 — —
De novo vs postsurgical/anastomotic stricture 1.4 (0.03–72.1) .82 — —
Length, 5 vs >5 cm 0.31 (0.015–6.2) .44 — —
Prestenotic dilation 0.30 (0.08–1.2) .084 0.31 (0.079–1.3) .099
PPI at the time of dilation 1.03 (0.22–4.9) .97 — —
Anti-TNF at time of dilation 3.6 (0.35–36.5) .28 — —
Graded dilation 1.9 (0.38–9.7) .43 — —
Abnormal mucosa at time of dilation 0.77 (0.19–3.1) .71 — —
Maximum caliber of dilation, 1-mm increment 1.2 (0.97–1.6) .092 — —
Steroid injection 0.40 (0.03–6.2) .50 — —
BMI, body mass index; EIM, extraintestinal manifestation; PPI, proton pump inhibitor.
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Supplementary Table 3. Analysis of Factors Associated With Recurrence of Symptoms After Clinical Efﬁcacy: Cox Marginal
Models: All Studies
Factor
Unadjusted analysis Multivariable analysis
HR (95% CI) P value HR (95% CI) P value
Female vs male 1.2 (0.70–2.1) .50 — —
Asian vs Caucasian 1.1 (0.65–2.0) .68 — —
BMI, 1-kg/m2 increment 0.97 (0.93–1.02) .29 — —
Family history of CD 0.99 (0.19–5.2) .99 — —
Smoking, past or present 1.08 (0.62–1.9) .80 — —
Age at diagnosis, 5-year increment 0.89 (0.75–1.04) .15 0.85 (0.72–1.00) .054
Age at time of stricture diagnosis, 5-year increment 1.02 (0.93–1.1) .65 — —
Age at time of dilation, 5-year increment 1.02 (0.93–1.1) .61 — —
Disease in jejunum/proximal ileum 1.8 (1.09–2.9) .022 2.1 (1.3–3.5) .003
Disease in ileocecum 1.4 (0.83–2.4) .20 1.6 (0.96–2.6) .073
Disease in colon 1.05 (0.63–1.7) .85 — —
Disease in rectum 1.2 (0.70–2.0) .50 — —
EIM 1.6 (0.88–2.8) .12 — —
Stomach stricture 1.6 (0.85–2.9) .15 — —
Duodenum stricture 0.74 (0.38–1.4) .37 — —
De novo vs postsurgical/anastomotic stricture 0.79 (0.29–2.1) .64 — —
Length, 5 vs >5 cm 0.41 (0.24–0.70) .001 — —
Prestenotic dilation 1.2 (0.68–2.0) .59 — —
PPI at the time of dilation 1.08 (0.58–2.0) .81 — —
Anti-TNF at time of dilation 1.2 (0.68–2.0) .56 — —
Graded dilation 1.01 (0.55–1.8) .98 — —
Abnormal mucosa at time of dilation 1.1 (0.65–2.0) .65 — —
Maximum caliber of dilation, 1-mm increment 0.96 (0.86–1.06) .41 — —
Steroid injection 0.62 (0.06–6.7) .69 — —
NOTE. Bolded and italicized values indicate P values < .05.
BMI, body mass index; EIM, extraintestinal manifestation; PPI, proton pump inhibitor.
Supplementary Table 4. Analysis of Factors Associated With Stricture Redilation: Cox Marginal Models: All Models
Factor
Unadjusted analysis Multivariable analysis
HR (95% CI) P value HR (95% CI) P value
Female vs male 1.3 (0.82–2.0) .28 — —
Asian vs Caucasian 2.8 (1.7–4.5) <.001 2.8 (1.8–4.5) <.001
BMI, 1-kg/m2 increment 0.97 (0.92–1.02) .24 — —
Family history of CD 0.37 (0.09–1.5) .17 — —
Smoking, past or present 0.91 (0.54–1.5) .73 — —
Age at diagnosis, 5-year increment 0.97 (0.87–1.09) .63 — —
Age at time of stricture diagnosis, 5-year increment 0.92 (0.81–1.04) .16 — —
Age at time of dilation, 5-year increment 0.92 (0.82–1.04) .18 — —
Disease in jejunum/proximal ileum 1.7 (1.1–2.6) .015 1.9 (1.2–2.9) .004
Disease in ileocecum 0.85 (0.55–1.3) .48 — —
Disease in colon 1.1 (0.74–1.7) .56 — —
Disease in rectum 0.85 (0.55–1.3) .46 — —
EIM 0.74 (0.44–1.2) .25 — —
Stomach stricture 1.2 (0.77–2.0) .40 — —
Duodenum stricture 0.91 (0.55–1.5) .73 — —
De novo vs postsurgical/anastomotic stricture 1.00 (0.58–1.7) .99 — —
Length, 5 vs >5 cm 0.49 (0.22–1.07) .075 — —
Prestenotic dilation 1.4 (0.90–2.2) .13 — —
PPI at the time of dilation 1.5 (0.86–2.6) .16 — —
Anti-TNF at time of dilation 0.81 (0.49–1.3) .42 — —
Graded dilation 0.80 (0.52–1.2) .31 — —
Abnormal mucosa at time of dilation 1.6 (1.00–2.6) .051 — —
Maximum caliber of dilation, 1-mm increment 1.03 (0.95–1.1) .44 — —
Steroid injection 0.35 (0.09–1.4) .13 — —
NOTE. Bolded and italicized values indicate P values < .05.
BMI, body mass index; EIM, extraintestinal manifestation; PPI, proton pump inhibitor.
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Supplementary Table 5. Analysis of Factors Associated With Stricture Surgery: Cox Marginal Models: All Studies
Factor
Unadjusted analysis Multivariable analysis
HR (95% CI) P value HR (95% CI) P value
Female vs male 0.81 (0.31–2.1) .67 — —
Asian vs Caucasian 1.7 (1.2–2.3) .003 0.96 (0.90–1.02) .15
BMI, 1-kg/m2 increment 0.91 (0.87–0.96) <.001 — —
Family history of CD 0.71 (0.51–0.99) .046 — —
Smoking, past or present 0.89 (0.39–2.1) .79 — —
Age at diagnosis, 5-year increment 1.03 (0.89–1.2) .68 — —
Age at time of stricture diagnosis, 5-year increment 0.95 (0.88–1.02) .18 — —
Age at time of dilation, 5-year increment 0.92 (0.87–0.98) .007 — —
Disease in jejunum/proximal ileum 1.4 (0.72–2.7) .32 — —
Disease in ileocecum 1.6 (0.90–2.9) .11 — —
Disease in colon 0.99 (0.63–1.5) .96 — —
Disease in rectum 0.73 (0.29–1.8) .51 — —
EIM 0.85 (0.51–1.4) .55 — —
Stomach stricture 1.2 (0.60–2.4) .61 — —
Duodenum stricture 0.78 (0.39–1.6) .49 — —
De novo vs postsurgical/anastomotic stricture 1.00 (0.55–1.8) .99 — —
Length, 5 vs >5 cm 0.79 (0.46–1.3) .38 — —
Prestenotic dilation 2.0 (1.4–2.7) <.001 1.9 (1.3–2.7) .001
PPI at the time of dilation 0.94 (0.48–1.9) .86 — —
Anti-TNF at time of dilation 1.6 (0.72–3.7) .24 — —
Graded dilation 0.88 (0.50–1.5) .65 — —
Abnormal mucosa at time of dilation 1.8 (0.67–4.8) .25 — —
Maximum caliber of dilation, 1-mm increment 0.90 (0.79–1.03) .12 — —
Steroid injection 1.8 (0.12–25.7) .68 — —
NOTE. Bolded and italicized values indicate P values < .05.
BMI, body mass index; EIM, extraintestinal manifestation; PPI, proton pump inhibitor.
Supplementary Table 6. Analysis of Factors Associated With Short-Term Clinical Efﬁcacy: Generalized Linear Mixed Models:
Published Studies*
Factor
Unadjusted analysis Adjusted analysis
OR (95% CI) P value OR (95% CI) P value
Female vs male 2.6 (0.52–12.5) .24 — —
Asian vs Caucasian 0.73 (0.01–52.6) .88 — —
BMI, 1-kg/m2 increment 1.1 (0.93–1.4) .19 — —
Family history of CD 0.62 (0.04–10.8) .74 — —
Smoking, past or present 5.5 (0.49–62.3) .16 — —
Age at diagnosis, 5-year increment 0.98 (0.68–1.4) .90 — —
Age at time of stricture diagnosis, 5-year increment 1.1 (0.83–1.5) .45 — —
Age at time of dilation, 5-year increment 1.2 (0.85–1.6) .35 — —
Disease in jejunum/proximal ileum 1.8 (0.28–11.7) .52 — —
Disease in ileocecum 0.35 (0.07–1.8) .20 0.32 (0.059–1.8) .20
Disease in colon 2.1 (0.43–10.6) .35 — —
Disease in rectum 5.2 (0.86–31.0) .071 — —
EIM 0.94 (0.15–5.7) .94 — —
Stomach stricture 1.00 (0.20–5.1) .99 — —
Duodenum stricture 1.2 (0.23–6.5) .80 — —
De novo vs postsurgical/anastomotic stricture 1.5 (0.012–150.2) .87 — —
Length, 5 vs >5 cm 0.25 (0.012–5.1) .37 — —
Prestenotic dilation 0.25 (0.05–1.2) .087 0.25 (0.050–1.2) .084
PPI at the time of dilation 1.3 (0.25–6.6) .76 — —
Anti-TNF at time of dilation 2.7 (0.23–31.3) .41 — —
Graded dilation 1.3 (0.16–10.5) .81 — —
Abnormal mucosa at time of dilation 1.01 (0.22–4.6) .98 — —
Maximum caliber of dilation, 1-mm increment 1.3 (1.00–1.8) .050 — —
Steroid injection 0.24 (0.01–5.5) .36 — —
BMI, body mass index; EIM, extraintestinal manifestation; PPI, proton pump inhibitor.
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Supplementary Table 7. Analysis of Factors Associated With Recurrence of Symptoms After Clinical Efﬁcacy: Cox Marginal
Models Factor: Published Studies*
Unadjusted analysis Multivariable analysis
HR (95% CI) P value HR (95% CI) P value
Female vs male 1.09 (0.60–2.0) .78 — —
Asian vs Caucasian 0.83 (0.47–1.5) .53 — —
BMI, 1-kg/m2 increment 0.97 (0.91–1.03) .27 — —
Family history of CD 0.90 (0.16–5.0) .90 — —
Smoking, past or present 1.05 (0.57–1.9) .89 — —
Age at diagnosis, 5-year increment 0.92 (0.80–1.07) .27 0.90 (0.77–1.04) .16
Age at time of stricture diagnosis, 5-year increment 1.01 (0.91–1.1) .86 — —
Age at time of dilation, 5-year increment 1.01 (0.91–1.1) .91 — —
Disease in jejunum/proximal ileum 1.5 (0.92–2.6) .10 1.7 (1.02–2.9) .042
Disease in ileocecal 1.2 (0.65–2.1) .60 — —
Disease in colon 0.73 (0.41–1.3) .28 — —
Disease in rectum 0.89 (0.50–1.6) .71 — —
EIM 1.2 (0.67–2.2) .50 — —
Stomach stricture 1.2 (0.62–2.5) .53 — —
Duodenum stricture 0.97 (0.45–2.1) .93 — —
De novo vs postsurgical/anastomotic stricture 0.23 (0.09–0.58) .002 — —
Length, 5 vs >5 cm 0.48 (0.26–0.87) .015 — —
Prestenotic dilation 0.64 (0.34–1.2) .18 0.65 (0.33–1.3) .22
PPI at the time of dilation 0.71 (0.30–1.6) .42 — —
Anti-TNF at time of dilation 0.95 (0.48–1.9) .88 — —
Graded dilation 1.5 (0.74–3.1) .25 — —
Abnormal mucosa at time of dilation 1.2 (0.67–2.2) .52 — —
Maximum caliber of dilation, 1-mm increment 0.94 (0.83–1.07) .33 — —
NOTE. Bolded and italicized values indicate P values < .05.
BMI, body mass index; EIM, extraintestinal manifestation; PPI, proton pump inhibitor.
Supplementary Table 8. Analysis of Factors Associated With Stricture Redilation: Cox Marginal Models: Published Studies*
Factor
Unadjusted analysis Multivariable analysis
HR (95% CI) P value HR (95% CI) P value
Female vs male 1.2 (0.75–2.0) .44 — —
Asian vs Caucasian 2.7 (1.7–4.3) <.001 3.6 (2.2–6.1) <.001
BMI, 1-kg/m2 increment 0.95 (0.90–1.01) .13 — —
Family history of CD 0.37 (0.09–1.5) .17 — —
Smoking, past or present 1.10 (0.65–1.8) .73 — —
Age at diagnosis, 5-year increment 1.00 (0.90–1.1) .99 — —
Age at time of stricture diagnosis, 5-year increment 0.94 (0.83–1.06) .29 — —
Age at time of dilation, 5-year increment 0.93 (0.82–1.05) .26 — —
Disease in jejunum/proximal ileum 1.5 (0.98–2.4) .060 1.5 (0.99–2.3) .056
Disease in ileocecum 0.81 (0.51–1.3) .37 — —
Disease in colon 0.96 (0.61–1.5) .86 — —
Disease in rectum 0.74 (0.46–1.2) .20 — —
EIM 0.62 (0.37–1.05) .075 — —
Stomach stricture 1.2 (0.75–2.0) .43 — —
Duodenum stricture 0.93 (0.54–1.6) .78 — —
De novo vs postsurgical/anastomotic stricture 1.2 (0.81–1.8) .35 — —
Length, 5 vs >5 cm 0.50 (0.23–1.08) .078 — —
Prestenotic dilation 1.08 (0.70–1.7) .74 — —
PPI at the time of dilation 1.2 (0.58–2.5) .62 — —
Anti-TNF at time of dilation 0.51 (0.31–0.82) .006 — —
Graded dilation 0.82 (0.51–1.3) .39 1.9 (1.2–3.0) .011
Abnormal mucosa at time of dilation 1.9 (1.04–3.3) .037 2.1 (1.09–3.9) .025
Maximum caliber of dilation, 1-mm increment 1.05 (0.97–1.1) .24 — —
Steroid injection 0.22 (0.05–0.94) .041 — —
NOTE. Bolded and italicized values indicate P values < .05.
BMI, body mass index; EIM, extraintestinal manifestation; PPI, proton pump inhibitor.
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Supplementary Table 9. Analysis of Factors Associated With Stricture Surgery: Cox Marginal Models: Published Studies*
Factor
Unadjusted analysis Multivariable analysis
HR (95% CI) P value HR (95% CI) P value
Female vs male 0.54 (0.24–1.2) .15 — —
Asian vs Caucasian 1.8 (1.4–2.3) <.001 3.0 (2.3–3.9) <.001
BMI, 1-kg/m2 increment 0.90 (0.88–0.92) <.001 — —
Family history of CD 0.69 (0.49–0.96) .029 — —
Smoking, past or present 0.74 (0.29–1.8) .51 — —
Age at diagnosis, 5-year increment 0.94 (0.85–1.05) .28 — —
Age at time of stricture diagnosis, 5-year increment 0.94 (0.90–0.97) <.001 — —
Age at time of dilation, 5-year increment 0.93 (0.89–0.96) <.001 — —
Disease in jejunum/proximal ileum 0.90 (0.43–1.9) .77 — —
Disease in ileocecum 1.9 (1.7–2.1) <.001 — —
Disease in colon 0.90 (0.67–1.2) .48 — —
Disease in rectum 0.73 (0.25–2.1) .56 — —
EIM 0.63 (0.35–1.1) .11 — —
Stomach stricture 1.4 (0.65–2.8) .42 — —
Duodenum stricture 0.67 (0.33–1.4) .28 — —
De novo vs postsurgical/anastomotic stricture 0.44 (0.02–10.8) .62 — —
Length, 5 vs >5 cm 0.73 (0.43–1.2) .24 — —
Prestenotic dilation 1.8 (1.08–2.9) .023 — —
PPI at the time of dilation 0.74 (0.31–1.8) .50 — —
Anti-TNF at time of dilation 2.0 (1.3–3.2) .003 3.5 (2.6–4.8) <.001
Graded dilation 0.87 (0.44–1.7) .68 — —
Abnormal mucosa at time of dilation 1.6 (0.63–3.8) .33 — —
Maximum caliber of dilation, 1-mm increment 0.89 (0.76–1.04) .14 — —
Steroid injection 21.5 (10.3–44.8) <.001 47.5 (24.8–91.1) <.001
NOTE. Bolded and italicized values indicate P values < .05.
BMI, body mass index; EIM, extraintestinal manifestation; PPI, proton pump inhibitor.
Supplementary Table 10.Outcomes by Dilation Number
Factor
First dilation (N ¼ 103)
Second dilation (N ¼
22) Third dilation (N ¼ 9)
P valuen Summary n Summary n Summary
Technical success 102 102 (100.0) 22 22 (100.0) 9 9 (100.0) —
Clinical success 87 75 (86.2) 20 17 (85.0) 9 8 (88.9) .96
Redilation 99 61 (61.6) 22 12 (54.5) 9 6 (66.7) .77
Months to redilation 61 2.0 [1.2, 6.0] 12 1.6 [1.02, 7.0] 6 9.1 [5.8, 16.8] .23
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